Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - Cantor Fitzgerald reiterated an Overweight rating and $15.00 price target on LifeMD Inc (NASDAQ:LFMD), maintaining it as a top pick for 2025. According to InvestingPro data, the stock appears undervalued, with analyst targets ranging from $8 to $18.
The research firm highlighted LifeMD as a differentiated telehealth provider with a clear path to product diversification over the long term. Management has reaffirmed its goals for 30% growth over the next three years and 25% EBITDA margins by the fourth quarter of 2028, compared to 11.4% in the second quarter of 2025. The company’s impressive 37.74% revenue growth and 87.57% gross profit margin in the last twelve months support these ambitious targets.
LifeMD plans to expand its business into women’s health, behavioral health, hormonal health, and additional areas. These expansions will help diversify its revenue stream from the current mix of 50% metabolic health and 50% lifestyle healthcare.
Cantor Fitzgerald views the current 6.9x EV/EBITDA valuation as undervalued compared to the 2025 peak of 14.7x. The firm maintains a positive outlook for LifeMD heading into third-quarter 2025 earnings.
The research firm’s analysis suggests LifeMD’s strategic diversification efforts and growth targets position the company favorably in the telehealth sector despite its current valuation.
In other recent news, LifeMD Inc. reported its financial results for the second quarter of 2025, which showed a larger-than-expected loss per share and a revenue shortfall compared to analyst projections. This earnings miss was primarily attributed to elevated customer acquisition costs within the company’s RexMD business segment, which accounts for a significant portion of LifeMD’s telehealth revenue. Following these results, KeyBanc lowered its price target for LifeMD from $14.00 to $12.00, while maintaining an Overweight rating on the stock. The RexMD unit, which focuses on treatments for men’s health issues, has been identified as a key area impacting financial performance. Despite the financial setback, KeyBanc’s continued Overweight rating indicates a positive long-term outlook from the firm. These developments reflect ongoing challenges and opportunities within LifeMD’s operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.